Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buflomedil for intermittent claudication.

T L M de Backer1, M Bogaert, R Vander Stichele

  • 1Ghent University, Heymans Institute of Pharmacology, De Pintelaan 185, Gent, Belgium, B-9000. tine.debacker@ugent.be

The Cochrane Database of Systematic Reviews
|October 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to achieve the desired outcomes of advance care planning in nursing homes: a theory of change.

BMC geriatrics·2018
Same author

Evidence-Based Medicine: A Few Introductory Remarks.

Acta clinica Belgica·2016
Same author

Selected Summaries.

Acta clinica Belgica·2016
Same author

Selected Summaries.

Acta clinica Belgica·2016
Same author

Systematic Quality Monitoring For Specialized Palliative Care Services: Development of a Minimal Set of Quality Indicators for Palliative Care Study (QPAC).

The American journal of hospice & palliative care·2016
Same author

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2015
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Buflomedil offers moderate improvements in walking distance for intermittent claudication (IC) patients. However, limited evidence and safety concerns warrant caution regarding its use for peripheral vascular disease.

Area of Science:

  • Vascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Intermittent claudication (IC) is characterized by exercise-induced limb pain due to chronic occlusive arterial disease.
  • Buflomedil is a vasoactive agent prescribed for peripheral vascular disease.
  • The clinical effectiveness of buflomedil specifically for IC remains inadequately examined.

Purpose of the Study:

  • To systematically evaluate the existing evidence on the efficacy of buflomedil in treating intermittent claudication.
  • To synthesize findings from randomized controlled trials comparing buflomedil to placebo for IC patients.

Main Methods:

  • Searched multiple databases (Cochrane, MEDLINE, IPA, Science Citation Index) and contacted manufacturers for relevant trials up to August 2007.
  • Included double-blinded, randomized controlled trials (RCTs) of oral buflomedil versus placebo in patients with IC (Fontaine stage II).

Related Experiment Videos

  • Assessed pain-free walking distance (PFWD) and maximum walking distance (MWD) using standardized exercise tests.

    • Main Results:

    • Two RCTs involving 127 participants met the inclusion criteria.
    • Buflomedil demonstrated statistically significant, moderate improvements in PFWD (75.1-80.6 m) and MWD (80.7-171.4 m) compared to placebo.
    • Improvements in walking distance were observed in both general IC and wholly diabetic populations.

    Conclusions:

    • The available evidence for buflomedil's efficacy in IC is limited, with most trials excluded due to poor quality.
    • Positive results from the two included trials are potentially biased by the exclusion of at least four unpublished, inconclusive studies.
    • Buflomedil's modest benefits must be weighed against safety concerns and its narrow therapeutic index.